Sansure Biotech

completed

 Sansure Biotech Inc. (“Sansure Biotech” or the “Company”) is an in vitro diagnostic (“IVD”) solution provider in China and engages in the production and sales of diagnostic reagents and instruments, and the provision of testing and research services. The Company’s headquarter is located at Changsha, Hunan Province, China and has two manufacturing bases and research and development (R&D) centers in Changsha and Shanghai as well as three clinical laboratories in Changsha, Beijing and Shanghai. The Company has partnered with over 2,000 hospitals and laboratories in China, and its technology has been deployed in over 160 countries. IFC is proposing a US$55 million A loan to Sansure Biotech to improve the Company’s export capacities through: i) construction of an automated manufacturing and R&D facility in Changsha; ii) expansion in Indonesia and Philippines to establish subsidiaries that will be responsible for sales, marketing, product development and technology support in the Southeast Asia region; and iii) setting up representative offices in Africa.  The project in Changsha will be developed in two phases. The first phase includes the construction of reagent production building expected to be completed by the end of 2022. The second phase of the project includes an instrument production building, and a staff dormitory building, that is planned to be completed by the end of 2024.  All the Company’s laboratories and manufacturing facilities are located within industrial parks in China. The first phase of production localization under this project in Indonesia and Philippines will be started with leasing production facility and purchase of equipment locally through voluntary market transaction.The Company is engaging with the Africa Medical Equipment Facility (AMEF) platform to leverage AMEF’s resources and financing solution provided for local healthcare small and medium-sized enterprises (SMEs).